Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1

Attention deficit hyperactivity disorder

Patient must have demonstrated a response to immediate-release methylphenidate hydrochloride with no emergence of serious adverse events; AND

Patient must require continuous coverage over 8 hours; AND

The treatment must not exceed a maximum daily dose of 80 mg of PBS-subsidised treatment with this drug; AND

Patient must be or have been diagnosed between the ages of 6 and 17 years inclusive; or

Patient must have had a diagnosis of ADHD prior to turning 18 years of age if PBS-subsidised treatment is continuing beyond 18 years of age; or

Patient must have a retrospective diagnosis of ADHD if PBS-subsidised treatment is commencing after turning 18 years of age; or

Patient must have had a retrospective diagnosis of ADHD if PBS-subsidised treatment is continuing in a patient who commenced PBS-subsidised treatment after turning 18 years of age; AND

Must be treated by a health practitioner who is any of: (i) a medical practitioner, (ii) a nurse practitioner who is continuing treatment with this medicine (of any strength) that was initiated by a medical practitioner as a PBS benefit.

A retrospective diagnosis of ADHD for the purposes of administering this restriction is:

(i) the presence of pre-existing childhood symptoms of ADHD (onset during the developmental period, typically early to mid-childhood); and

(ii) documentation in the patient's medical records that an in-depth clinical interview with, or, obtainment of evidence from, either a: (a) parent, (b) teacher, (c) sibling, (d) third party, has occurred and which supports point (i) above.